Evidence map›Paper›PMID 26610467›Full record

ArticleInternational journal of molecular sciences2015

Application of Wnt Pathway Inhibitor Delivering Scaffold for Inhibiting Fibrosis in Urethra Strictures: In Vitro and in Vivo Study.

Kaile Zhang, Xuran Guo, Weixin Zhao, Guoguang Niu, Xiumei Mo, Qiang Fu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Tissue engineering of urethra: Systematic review of recent literature.Experimental biology and medicine (Maywood, N.J.) · 2017
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Bioactive materials forBioactive materials · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Electrospinning: Application and Prospects for Urologic Tissue Engineering.Frontiers in bioengineering and biotechnology · 2020
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kaile ZhangThe Department of Urology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Yishan Road 600, Shanghai 200233, China. great_z0313@126.com.
Xuran GuoBiomaterials and Tissue Engineering Laboratory, College of Chemistry & Chemical Engineering and Biotechnology, Donghua University, North Renmin Road 2999, Shanghai 201620, China. ibmguoxuran@163.com.
Weixin ZhaoWake Forest Institute for Regenerative Medicine, 391 Technology Way, Winston-Salem, NC 27101, USA. wezhao@wakehealth.edu.
Guoguang NiuWake Forest Institute for Regenerative Medicine, 391 Technology Way, Winston-Salem, NC 27101, USA. gniu@wakehealth.edu.
Xiumei MoBiomaterials and Tissue Engineering Laboratory, College of Chemistry & Chemical Engineering and Biotechnology, Donghua University, North Renmin Road 2999, Shanghai 201620, China. xmm@dhu.edu.cn.
Qiang FuThe Department of Urology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Yishan Road 600, Shanghai 200233, China. jamesqfu@aliyun.com.
Donghua University · CNForest Institute · USShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the mechanical property and biocompatibility of the Wnt pathway inhibitor (ICG-001) delivering collagen/poly(L-lactide-co-caprolactone) (P(LLA-CL)) scaffold for urethroplasty, and also the feasibility of inhibiting the extracellular matrix (ECM) expression in vitro and in vivo.

methodsICG-001 (1 mg (2 mM)) was loaded into a (P(LLA-CL)) scaffold with the co-axial electrospinning technique. The characteristics of the mechanical property and drug release fashion of scaffolds were tested with a mechanical testing machine (Instron) and high-performance liquid chromatography (HPLC). Rabbit bladder epithelial cells and the dermal fibroblasts were isolated by enzymatic digestion method. (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay) and scanning electron microscopy (SEM) were used to evaluate the viability and proliferation of the cells on the scaffolds. Fibrolasts treated with TGF-β1 and ICG-001 released medium from scaffolds were used to evaluate the anti-fibrosis effect through immunofluorescence, real time PCR and western blot. Urethrography and histology were used to evaluate the efficacy of urethral implantation.

resultsThe scaffold delivering ICG-001 was fabricated, the fiber diameter and mechanical strength of scaffolds with inhibitor were comparable with the non-drug scaffold. The SEM and MTT assay showed no toxic effect of ICG-001 to the proliferation of epithelial cells on the collagen/P(LLA-CL) scaffold with ICG-001. After treatment with culture medium released from the drug-delivering scaffold, the expression of Collagen type 1, 3 and fibronectin of fibroblasts could be inhibited significantly at the mRNA and protein levels. In the results of urethrography, urethral strictures and fistulas were found in the rabbits treated with non-ICG-001 delivering scaffolds, but all the rabbits treated with ICG-001-delivering scaffolds showed wide caliber in urethras. Histology results showed less collagen but more smooth muscle and thicker epithelium in urethras repaired with ICG-001 delivering scaffolds.

conclusionAfter loading with the Wnt signal pathway inhibitor ICG-001, the Collagen/P(LLA-CL) scaffold could facilitate a decrease in the ECM deposition of fibroblasts. The ICG-001 delivering Collagen/P(LLA-CL) nanofibrous scaffold seeded with epithelial cells has the potential to be a promising substitute material for urethroplasty. Longer follow-up study in larger animals is needed in the future.

Indexed as

Tissue ScaffoldsAnimalsBridged Bicyclo Compounds, HeterocyclicCell ProliferationCollagen Type IConstriction, PathologicDelayed-Action PreparationsDrug Delivery SystemsEpithelial CellsFibrosisMalePyrimidinonesRabbitsTissue EngineeringTransforming Growth Factor beta1UrethraBridged Bicyclo Compounds, HeterocyclicCollagen Type IDelayed-Action PreparationsICG 001PyrimidinonesTransforming Growth Factor beta1electrospinningregenerative medicinetissue engineeringurethraWnt signaling pathway

Identifiers

PMID26610467
PMCPMC4661908
OpenAlexW2175105745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.